From: GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1
Features | No. of patients | GSG2 expression | p value | |
---|---|---|---|---|
Low | High | |||
All patients | 116 | 49 | 67 | Â |
Age (years) | Â | Â | Â | 0.852 |
 ≤ 58 | 58 | 24 | 34 |  |
 > 58 | 58 | 25 | 33 |  |
Grade | Â | Â | Â | 0.033 |
 I | 1 | 0 | 1 |  |
 II | 67 | 34 | 33 |  |
 III | 40 | 11 | 29 |  |
T Infiltrate | Â | Â | Â | 0.968 |
 T1 | 32 | 14 | 18 |  |
 T2 | 68 | 28 | 40 |  |
 T3 | 11 | 4 | 7 |  |
T4 | 2 | 2 | 0 | Â |
N stage | Â | Â | Â | 0.696 |
 N0 | 61 | 28 | 33 |  |
 N1 | 30 | 11 | 19 |  |
 N2 | 17 | 6 | 11 |  |
 N3 | 6 | 4 | 2 |  |
AJCC stage | Â | Â | Â | 0.695 |
 1 | 22 | 8 | 14 |  |
 2 | 62 | 28 | 34 |  |
 3 | 28 | 12 | 16 |  |
Tumor size | Â | Â | Â | 0.835 |
 ≤ 3 cm | 67 | 29 | 38 |  |
 > 3 cm | 46 | 19 | 27 |  |